MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) announced today that the US biotechnology company, ImmunoGen Inc., has licensed access to the MorphoSys HuCAL GOLD® library for use in ImmunoGen's internal target research programs. ImmunoGen will pay MorphoSys subscription fees during the one-year term of the agreement. Further financial details were not disclosed.
In June 2001, ImmunoGen and MorphoSys entered into a collaboration to use MorphoSys's previous version of the HuCAL® library (Human Combinatorial Antibody Library) in ImmunoGen's internal research programs. The four-year term of this prior agreement ended in May 2005.
The two companies also have a separate collaboration, established in September 2000, to develop a fully human antibody against an ImmunoGen-provided cell-surface target associated with various forms of cancer.
“We are delighted that ImmunoGen continues to see our HuCAL® antibody technology as a valuable asset in its target research programs and is upgrading to the most sophisticated version, HuCAL GOLD®,” commented Dr. Simon Moroney, Chief Executive Officer, MorphoSys AG.